» Articles » PMID: 36589817

Understanding Gut-liver Axis Nitrogen Metabolism in Fatty Liver Disease

Overview
Specialty Endocrinology
Date 2023 Jan 2
PMID 36589817
Authors
Affiliations
Soon will be listed here.
Abstract

The homeostasis of the most important nitrogen-containing intermediates, ammonia and glutamine, is a tightly regulated process in which the gut-liver axis plays a central role. Several studies revealed that nitrogen metabolism is altered in Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD), a consensus-driven novel nomenclature for Non-Alcoholic Fatty Liver Disease (NAFLD), the most common chronic liver disease worldwide. Both increased ammonia production by gut microbiota and decreased ammonia hepatic removal due to impaired hepatic urea cycle activity or disrupted glutamine synthetase activity may contribute to hepatic ammonia accumulation underlying steatosis, which can eventually progress to hyperammonemia in more advanced stages of steatohepatitis and overt liver fibrosis. Furthermore, our group recently showed that augmented hepatic ammoniagenesis increased glutaminase activity and overexpression of the high activity glutaminase 1 isoenzyme occurs in Fatty Liver Disease. Overall, the improved knowledge of disrupted nitrogen metabolism and metabolic miscommunication between the gut and the liver suggests that the reestablishment of altered gut-liver axis nitrogenous balance is an appealing and attractive therapeutic approach to tackle Fatty Liver Disease, a growing and unmet health problem.

Citing Articles

The Therapeutic Potential of the Specific Intestinal Microbiome (SIM) Diet on Metabolic Diseases.

Chu N, Chow E, Chan J Biology (Basel). 2024; 13(7).

PMID: 39056692 PMC: 11273990. DOI: 10.3390/biology13070498.


Influence of Lipid Class Used for Omega-3 Fatty Acid Supplementation on Liver Fat Accumulation in MASLD.

Sabinari I, Horakova O, Cajka T, Kleinova V, Wieckowski M, Rossmeisl M Physiol Res. 2024; 73(Suppl 1):S295-S320.

PMID: 39016154 PMC: 11412347. DOI: 10.33549/physiolres.935396.


Gut liver brain axis in diseases: the implications for therapeutic interventions.

Yan M, Man S, Sun B, Ma L, Guo L, Huang L Signal Transduct Target Ther. 2023; 8(1):443.

PMID: 38057297 PMC: 10700720. DOI: 10.1038/s41392-023-01673-4.

References
1.
Tomomura M, Tomomura A, Dewan M, Saheki T . Long-chain fatty acids suppress the induction of urea cycle enzyme genes by glucocorticoid action. FEBS Lett. 1996; 399(3):310-2. DOI: 10.1016/s0014-5793(96)01344-0. View

2.
De Chiara F, Thomsen K, Habtesion A, Jones H, Davies N, Gracia-Sancho J . Ammonia Scavenging Prevents Progression of Fibrosis in Experimental Nonalcoholic Fatty Liver Disease. Hepatology. 2019; 71(3):874-892. DOI: 10.1002/hep.30890. View

3.
Gokcen P, Ozturk O, Adali G, Tosun I, Dogan H, Kara H . A novel therapeutic approach to NASH: Both polyethylene glycol 3350 and lactulose reduce hepatic inflammation in C57BL/6J mice. Adv Clin Exp Med. 2021; 30(11):1167-1174. DOI: 10.17219/acem/140506. View

4.
Mato J, Martinez-Chantar M, Lu S . Methionine metabolism and liver disease. Annu Rev Nutr. 2008; 28:273-93. DOI: 10.1146/annurev.nutr.28.061807.155438. View

5.
Eriksen P, Vilstrup H, Rigbolt K, Suppli M, Sorensen M, Heeboll S . Non-alcoholic fatty liver disease alters expression of genes governing hepatic nitrogen conversion. Liver Int. 2019; 39(11):2094-2101. DOI: 10.1111/liv.14205. View